Drug Profile
AZD 6482
Alternative Names: AZD6482Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 05 May 2022 The George Institute in collaboration with Heart Research Institute plans a phase II trial for Stroke (Adjuvant therapy) in Australia (IV), in October 2022 (NCT05363397)
- 29 Jul 2010 Discontinued - Phase-I for Thrombosis in Sweden (IV)
- 31 May 2008 AstraZeneca completes a phase I trial in Thrombosis in Sweden